Skip to main content

Table 2 Schedule of Activities (SoA) for patients enrolled in treatment-cohort

From: Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway

Study procedures

Screening

Treatment cohort

Treatment phase

EOT

Survival FU

(D 1–21)

D1g

W8g

W16g

W26g

W39h

QW13h

 

Q26W for

2 years after end of treatment

Check inclusion criteria and exclusion criteria for treatment phase + Drug specific selection criteria

X

        

 Informed consenta

X

        

 Medical history

X

        

 Drug dispensingb

 

X

X

X

X

X

X

  

 Physical examination

X

 

X

X

X

X

X

X

 

 Vital signs and ECOG PS

X

X

X

X

X

X

X

X

 

 ECG

X

        

 AE/SAE assessment

X

 

X

X

X

X

X

X

 

 Concomitant medication

X

 

X

X

X

X

X

X

 

 QoL (V)

X

  

X

X

X

X

X

 

 Laboratory Assessmentsc

X

 

X

X

X

X

X

X

 

 Pregnancy testd, e

X

Monthly as long as use of contraception is required, see drug specific amendment

Central lab sampling

X

        

 Plasma/serum samples

X

 

X

X

X

X

X

X

 

 Urinei

X

 

X

    

X

 

 Fecesi

X

 

X

      

 Tumor biopsy

X

  

X

   

X

 

 Other materialf

X

 

X

X

   

X

 

Tumor assessment

X

 

X

X

X

X

X

X

 

Survival follow-up

        

X

  1. aDrug specific informed consent
  2. bTreatment according to drug specific manuals
  3. cPatients should be routinely monitored for serum creatinine and electrolytes (including magnesium) while on therapy. Liver function (including AST and ALT) should be monitored monthly during the first 6 months of treatment, and as clinically indicated thereafter.
  4. dLess than 72 h before treatment
  5. eIf patient is sexual abstinent, there is no need for pregnancy testing, but the patient must confirm abstinence monthly
  6. fPleural, effusion/ascites collected when possible/available
  7. gVisit window +/− 7 days, year 1.
  8. hVisit window +/− 14 days after year 1.
  9. iSelected cohorts only